Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Research Support, Non-U.S. Gov't

Randomized Controlled Trial

Multicenter Study

Comparative Study

Clinical Trial

Research Support, N.I.H., Extramural

Review

Observational Study

Meta-Analysis

Systematic Review

Clinical Trial, Phase II

Clinical Trial, Phase I

Clinical Trial, Phase IV

Letter

Clinical Trial, Phase III

Research Support, N.I.H., Intramural

Case Reports

Scoping Review

Clinical Trial Protocol

Corrected and Republished Article

Controlled Clinical Trial

Publication Year

From

Quick links

Individual year

2023

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Atazanavir Sulfate""[mesh_terms]

89 Results

Searching titles within these results

Atazanavir: new option for treatment of HIV infection.

Diane V Havlir, Steven D O'Marro

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;38(11):1599-604

Full Text

Abstract

Atazanavir-induced unconjugated hyperbilirubinemia prevents vascular hyporeactivity during experimental human endotoxemia.

Mirrin J Dorresteijn, Douwe Dekker, Jelle Zwaag, Suzanne Heemskerk, Hennie M J Roelofs, Paul Smits, Johannes G van der Hoeven, Frank A D T G Wagener, Peter Pickkers

Frontiers in immunology 2023;14():1176775

Free Full Text

Abstract

Contemporary protease inhibitors and cardiovascular risk.

Jens Lundgren, Amanda Mocroft, Lene Ryom

Current opinion in infectious diseases 2019;31(1):8-13

Full Text

Abstract

Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.

Michael Neely, Laurent Decosterd, Aurélie Fayet, Janice Soo Fern Lee, Ashley Margol, Meera Kanani, Julia di Iulio, Tido von Schoen-Angerer, Roger Jelliffe, Alexandra Calmy

Antimicrobial agents and chemotherapy 2011;54(11):4619-25

Free Full Text

Abstract

Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.

Marian Iwamoto, Larissa A Wenning, Goutam C Mistry, Amelia S Petry, Sarah Y Liou, Kaylan Ghosh, Sheila Breidinger, Neal Azrolan, Maria J Gutierrez, William E Bridson, Julie A Stone, Keith M Gottesdiener, John A Wagner

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;47(1):137-40

Full Text

Abstract

A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction.

J Baril, B Conway, P Giguère, N Ferko, S Hollmann, J B Angel

HIV medicine 2014;15(5):301-10

Free Full Text

Abstract

Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose.

Michael Gartner, Lilly East, Patrick Larson, Chandni Valiathan, Rajesh Krishna, Kathleen Deschamps, Julie Ann Luk, Crystal Bethel-Brown, Helen Manthos, John Brejda

Biopharmaceutics & drug disposition 2017;37(9):533-541

Full Text

Abstract

Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteers.

Javier A Estévez, José Moltó, Laura Tuneu, Samandhy Cedeño, Rosa M Antonijoan, Maria A Mangues, Bonaventura Clotet, Pere Domingo, Montse Puntes, Manuel J Barbanoj, Marta Valle

The Journal of antimicrobial chemotherapy 2012;67(8):2013-9

Full Text

Abstract

Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.

Ighovwerha Ofotokun, Lumine H Na, Raphael J Landovitz, Heather J Ribaudo, Grace A McComsey, Catherine Godfrey, Francesca Aweeka, Susan E Cohn, Manish Sagar, Daniel R Kuritzkes, Todd T Brown, Kristine B Patterson, Michael F Para, Randi Y Leavitt, Angelina Villasis-Keever, Bryan P Baugh, Jeffrey L Lennox, Judith S Currier

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016;60(12):1842-51

Free Full Text

Abstract

Switching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy With Hypercholesterolemia: A Randomized Controlled Trial.

Phanthaboon Wangpatharawanit, Somnuek Sungkanuparph

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2017;63(6):818-20

Full Text

Abstract

Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers.

Laurenzia Ferraris, Ottavia Viganò, Anna Peri, Maciej Tarkowski, Greta Milani, Stefano Bonora, Fulvio Adorni, Cristina Gervasoni, Emilio Clementi, Giovanni Di Perri, Massimo Galli, Agostino Riva

The Journal of antimicrobial chemotherapy 2013;67(9):2236-42

Full Text

Abstract

Releasing the true power of protease inhibitors.

F Raffi

International journal of STD & AIDS 2004;14 Suppl 1():29-33

Full Text

Abstract

Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia.

Ulrike Möbius, Margrit Lubach-Ruitman, Brigitte Castro-Frenzel, Matthias Stoll, Stefan Esser, Esther Voigt, Stefan Christensen, Jörg-Andres Rump, Gerd Fätkenheuer, Georg M N Behrens, Reinhold E Schmidt

Journal of acquired immune deficiency syndromes (1999) 2005;39(2):174-80

Full Text

Abstract

Elevated alkaline phosphatase with raltegravir in a treatment experienced HIV patient.

Eric Fleischbein, John O'Brien, Ryan Martelino, Martin Fenstersheib

AIDS (London, England) 2009;22(17):2404-5

Full Text

Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir.

Michael Sension, Jose Luiz de Andrade Neto, Beatriz Grinsztejn, Jean Michel Molina, Isidro Zavala, Juan González-García, Alice Donnelly, Phillip Phiri, Emilio Ledesma, Donnie McGrath

Journal of acquired immune deficiency syndromes (1999) 2009;51(2):153-62

Full Text

Abstract

Results: 1 – 15 / 89

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Atazanavir Sulfate""[mesh_terms]

Atazanavir: new option for treatment of HIV infection.

Atazanavir-induced unconjugated hyperbilirubinemia prevents vascular hyporeactivity during experimental human endotoxemia.

Contemporary protease inhibitors and cardiovascular risk.

Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.

Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.

A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction.

Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose.

Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteers.

Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.

Switching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy With Hypercholesterolemia: A Randomized Controlled Trial.

Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers.

Releasing the true power of protease inhibitors.

Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia.

Elevated alkaline phosphatase with raltegravir in a treatment experienced HIV patient.

Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir.

Results for
""Atazanavir Sulfate""[mesh_terms]